Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
NOVA Stock Chart & Stats
€39.95
€2.60(3.26%)
At close: 4:00 PM EST
€39.95
€2.60(3.26%)
Day’s Range― - ―
52-Week Range€36.10 - €90.40
Previous CloseN/A
Volume1.40K
Average Volume (3M)4.96K
Market Cap
$181.10B
Enterprise Value€1.35T
Total Cash (Recent Filing)$26.96B
Total Debt (Recent Filing)$130.96B
Price to Earnings (P/E)12.9
Beta0.97
Next Earnings
May 06, 2026EPS Estimate
0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding3,390,128,000
10 Day Avg. Volume4,001
30 Day Avg. Volume4,959
Financial Highlights & Ratios
PEG Ratio8.49
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio25.38
Enterprise Value/Market Cap7.46
Enterprise Value/Revenue4.55
Enterprise Value/Gross Profit5.62
Enterprise Value/Ebitda8.82
Forecast
1Y Price Target
$48.21Price Target Upside20.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Management And Pipeline FocusAnalyst highlights the new CEO's emphasis on stronger commercial execution and targeted pipeline strengthening, which could improve launch effectiveness and business development outcomes.
Regulatory ApprovalAnalyst notes FDA approval of oral semaglutide (Wegovy pill) provides a first‑mover advantage that can help the company regain incretin market share by attracting patients who prefer an oral option.
Untapped Obesity MarketAnalyst observes a large untapped obesity treatment market and says oral therapies could expand access and drive volume growth as many patients wait for lower‑cost or oral alternatives.
Bears Say
Competitive ThreatsAnalyst expects intense competition from Lilly and emerging oral and next‑generation GLP‑1 developers to continue eroding market share from core diabetes and obesity products.
Guidance And Earnings RiskAnalyst notes that weaker revenue and profit guidance, after removing one‑time benefits, points to underlying earnings pressure and could weigh on the company's valuation.
Pricing And Access PressuresAnalyst warns that pricing concessions and policy‑driven access changes in the United States are likely to reduce revenue from injectable GLP‑1 medicines and pressure gross margins.
Novo Nordisk News
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €36.10 and its highest was €90.40 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $181.10B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is May 06, 2026 which is in 89 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Feb 04, 2026. The company reported €0.809 earnings per share for the quarter, beating the consensus estimate of €0.783 by €0.026.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.7.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.809 in its last earnings report, beating expectations of €0.783. Following the earnings report the stock price went down -6.11%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.21 (20.69% Upside)
$48.21 (20.69% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 87%
Sector Average 69%
Sector Average 69%
News Sentiment
Bearish
Bullish news 35%
Bearish news 65%
Bearish news 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.43%
12-Months-Change
Fundamentals
Return on Equity
61.25%
Trailing 12-Months
Asset Growth
31.99%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NOVA Company Deck
NOVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum in obesity and GLP-1 franchises (notably the successful Wegovy pill launch, robust GLP-1 volume share, and meaningful R&D readouts such as CagriSema and zenagamtide) alongside solid cash generation and shareholder returns. Offsetting these positives are substantial near-term headwinds driven by pricing pressure, policy impacts (MFN/MFP), loss of exclusivity risk, margin compression and a conservative 2026 outlook (adjusted sales and operating profit guidance of -5% to -13% CER). Management is bullish on long-term market expansion and pipeline potential but explicit near-term guidance and exceptional costs temper the tone. Overall, positives (product launches, R&D wins, market leadership and cash generation) are significant, but the company has signaled a pronounced near-term earnings challenge driven by pricing and policy — producing a balanced, watchful outlook.View all DE:NOVA earnings summariesNOVA Stock 12 Month Forecast
Average Price Target
€48.21
▲(20.69% Upside)
Technical Analysis
Options Prices
Currently, No data available
---